Accretion Nutraveda was incorporated on March 16, 2021. The company manufactures ayurvedic and nutraceutical products for other brands on a contract basis. It produces tablets, capsules, liquids, powders, oils, and external products, supplying domestic customers and export markets such as Sri Lanka, Singapore, and the United States
| Bidding Dates |
|---|
| 28 Jan 2026 - 30 Jan 2026 |
| Subscription |
|---|
| 1.77x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,44,000 | 2 | 2 | 1000 | 1.9 M | ₹122 - ₹129 | 73.48 % | ₹234.2 M - ₹247.7 M | RHP DOC |
Accretion Nutraveda IPO SUBSCRIPTION STATUS
30 Jan '26Accretion Nutraveda IPO overall subscription rate was 1.77 times the total available shares
Accretion Nutraveda IPO retail subscription rate was 2.92 times in the retail segment
Accretion Nutraveda IPO non-institutional investor subscription rate was 3.24 times in the non-institutional investor category
Accretion Nutraveda IPO Qualified Institutional Bidder subscription rate was 0.53 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
30 Jan 2026 (Day 3) | 2.92x | 3.24x | 0.53x |
29 Jan 2026 (Day 2) | 0.57x | 1.33x | 0.53x |
28 Jan 2026 (Day 1) | 0.28x | 0.61x | 0x |
Accretion Nutraveda FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| H1FY26 | 14.1 | 2.3 | -0.9 | -0.9 | 23.4% |
| FY25 | 16.0 | 2.6 | -2.2 | -3.1 | 22.8% |
| FY24 | 5.0 | 0.8 | 0.2 | 0.1 | 24.1% |
| FY23 | 2.9 | 0.3 | 0.7 | 0.7 | 20.4% |
Accretion Nutraveda IPO SUBSCRIPTION STATUS DETAILS
Accretion Nutraveda had 1.9 M shares on offer
Accretion Nutraveda IPO offer price was in the range ₹122 - ₹129
Accretion Nutraveda IPO minimum Investment was ₹244000
Accretion Nutraveda IPO issue size was ₹ 234.2 M - ₹ 247.7 M
Accretion Nutraveda had a minimum lot size of 1000 Shares per application
Accretion Nutraveda NUMBER OF SHARES ON OFFER
Accretion Nutraveda IPO IMPORTANT DATES
| Issue Open Date | 28 Jan 2026 |
| Issue close Date | 30 Jan 2026 |
| Allotment Date | 02 Feb 2026 |
| Refund Date | 03 Feb 2026 |
| Demat Account Credit Date | 03 Feb 2026 |
| Listing Date | 04 Feb 2026 |
| Listing on Exchange(s) | BSE |
| Accretion Nutraveda Allotment Status | Exchange/ Registrar |
Accretion Nutraveda IPO subscription opened on 28 Jan 2026, and closed on 30 Jan 2026
IPO allotment for Accretion Nutraveda was finalized on Monday, 02 Feb 2026
IPO listing for Accretion Nutraveda was on BSE on Wednesday, 04 Feb 2026
Accretion Nutraveda IPO LISTING GAINS
| Issue Price (adjusted) | 129.0 |
| Listing Open Price | 191.0 |
| Listing Close Price | 191.2 |
| Listing Gain% | 48.1% |
| Current Gain% | 135.3% |
Accretion Nutraveda Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accretion Nutraveda Ltd. | 303.5 | 219.7 | 43.4 | 0.5 | 6.5 | 14.3 | 12.1 | 33.7 | 110 | 5.1 | 94 | 7 | 94 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Accretion Nutraveda INFORMATION ON IPO ISSUE
About Accretion Nutraveda
Accretion Nutraveda was incorporated on March 16, 2021. The company manufactures ayurvedic and nutraceutical products for other brands on a contract basis. It produces tablets, capsules, liquids, powders, oils, and external products, supplying domestic customers and export markets such as Sri Lanka, Singapore, and the United States
Object of the Issue
- Purchase of machineries for automation in existing manufacturing unit
- Purchase of machineries for new manufacturing setup
- Funding working capital requirements of the company
- General corporate purposes
Accretion Nutraveda - PROMOTERS
| Name |
|---|
| Mayur Popatlal Sojitra |
| Ankurkumar Shantilal Patel |
| Paraskumar Vinubhai Parmar |
| Hardik Mukundbhai Prajapati |
| Harshad Nanubhai Rathod |
| Vivek Ashok Kumar Patel |
Accretion Nutraveda - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Mayur Popatlal Sojitra | Managing Director |
| Ankurkumar Shantilal Patel | Whole Time Director |
| Paraskumar Vinubhai Parmar | CFO & Executive Director |
| Hardik Mukundbhai Prajapati | Non-Executive Director |
| Harshad Nanubhai Rathod | Non-Executive Director |
| Vivek Ashok Kumar Patel | Non- Executive Director |
| Arun Dash | Independent Director |
| Mahipal Singh Chouhan | Independent Director |
| Shruti Gupta | Independent Director |
Accretion Nutraveda Book Running Lead Manager
Sobhagya Capital Options Private Limited
cs@sobhagyacap.com
Accretion Nutraveda Registrar to the issue
KFin Technologies Limited
apl.ipo@kfintech.com
Accretion Nutraveda Strengths
Diverse product range
The company operates in the nutraceutical and Ayurveda segments and offers a portfolio of over 72 formulations. This broad product range allows the company to address varied consumer needs across preventive and therapeutic categories
Strong quality systems
The company follows strict quality control processes across all stages of manufacturing to ensure product safety, consistency, and effectiveness. It has established quality assurance and quality control systems to comply with Food Safety and Standards Authority of India (FSSAI), Ministry of AYUSH, Good Manufacturing Practices (GMP), and other regulatory requirements
Stable relationships
The company has built long-standing relationships with both clients and suppliers, which support smooth procurement and distribution activities. The promoters, who are directly involved in sales and marketing, oversee and manage these relationships through ongoing business and operational interactions
Accretion Nutraveda Risks
Operational disruption risk
The company’s manufacturing and processing activities are dependent on a single facility in Sanand, Gujarat. Any disruption due to equipment failure, industrial accidents, fire, severe weather conditions, natural disasters, or planned shutdowns for maintenance and statutory inspections may interrupt production
Customer concentration risk
The company derives a significant portion of its revenue from a limited number of customers. The loss of any key customer or a reduction in order volumes could negatively impact revenue and profitability
Geographic concentration risk
A large share of the company’s revenue is concentrated in Gujarat, increasing exposure to regional economic, regulatory, and competitive risks. Limited presence in other markets may constrain growth opportunities
IPO FAQs
The promoters of the company are Mayur Popatlal Sojitra, Ankurkumar Shantilal Patel, Paraskumar Vinubhai Parmar, Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod and Vivek Ashok Kumar Patel.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 122.0 - 129.0.
The IPO application opens on Jan 28, 2026 and closes on Jan 30, 2026.
The minimum lot size for the IPO is 2000. The maximum lot size for the IPO is 2000.
For all category investors, the minimum application amount for this IPO is Rs. 244,000.0, the maximum value for this IPO is Rs 258,000.0.
This IPO will be allotted on Feb 02, 2026.
The refund will be credited to your account on Feb 03, 2026.
The allotted shares will be credited to your demat on Feb 03, 2026.
Accretion Nutraveda Ltd.’s shares listed on the stock exchanges on Feb 04, 2026.